ARIAD Presents Preclinical Data On Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity In Solid Tumors

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented, for the first time, results of studies on its investigational, multi-targeted kinase inhibitor - AP24534 - showing anti-tumor activity in preclinical cancer models. These data were released at the EORTC-NCI-AACR (ENA) symposium on “Molecular Targets and Cancer Therapeutics” held in Geneva, Switzerland this week.

More: continued here

Filed under: Cancer on October 28th, 2008